blood pressure regulation, mineralocorticoids have a crucial role in maintaining the homeostasis of salt, water, and vascular tone through the renin-angiotensin-aldosterone system. Aldosterone activates the mineralocorticoid receptor (MR) in epithelial tissues and regulates the sodium transport. The aldosterone/MR complex could also contribute to an inflammatory response, which is characterized by vascular infiltration of immune cells, oxidative stress, and proinflammatory cytokine production and contributes to the damage in renal, heart, and vascular tissue. Although several research groups have proposed that MR biological activity is influenced by factors other than aldosterone, recent studies have revealed a cross-talk between Rac1, a small GTP-binding protein, and MR activation independent of aldosterone, which would be associated with the development of salt-sensitive hypertension and cardiovascular damage. 5 Rac1 is a member of the Rho family of GTPases, and it cycles between an inactive GDP-bound and an active GTPbound state. 6 The primary Rac1 transcript gives rise to 2 messenger RNAs: Rac1a (1.2 kD in size) and Rac1b (2.5 kD in size). 7 Rac1a is stabilized in its GDP-bound form in the cytoplasm through an interaction with Rho-GDI. 8 The Rac1b isoform is a variant product that contains an additional 57 nucleotides, resulting in an in-frame insertion of 19 new amino acids. 9 Unlike Rac1a, the Rac1b isoform displays a faster GDP/GTP exchange rate, does not bind Rho-GDI, and does not require external stimulus for activation, and is therefore constitutively bound to the plasma membrane. 6, 10 Rac1 is part of the NADPH oxidase complex, which induces the generation of reactive oxygen species, such as superoxide (O 2 − ) and hydrogen peroxide (H 2 O 2 ), which lead to increased oxidative stress, alterations in the cell membrane, and endothelial damage. In fact, oxidative stress has been shown to play a key role in cardiac pathologies associated with MR, 11 possibly through the activation of nuclear factor B (NF-kB), an important transcription factor of many proinflammatory cytokines. 12 However, few reports investigate the regulation of Rac1 expression through an MR-dependent mechanism in renal disease.
The importance of inflammation and oxidative stress in human cardiovascular disease is supported by studies from Zalba et al., 13 who demonstrated that polymorphisms in NADPH oxidase subunits are associated with increased atherosclerosis and hypertension. However, hypertension has not been associated with polymorphisms in the RAC1 gene, but as observed previously, it has been proposed that alterations of Rac1, by impairment of its activity, in its expression, or of its associated proteins (e.g., GEFs), could influence susceptibility to diseases such as renal and/or cardiac failure or hypertension. 14 Rac1 is implicated in a variety of diseases, and it is known that single nucleotide polymorphisms (SNPs) may confer disease susceptibility, as well as determine the disease severity and progression. In 2011, a study genotyping the polymorphism rs10951982 (G>A) located in intron 1 of RAC1 was conducted in a European cohort, which demonstrated a decrease in RAC1 gene expression in peripheral leukocytes. 15 In this study, we evaluated 2 polymorphisms in the RAC1 gene (NG_029431) that could affect the Rac1 protein expression and then determined the association of both polymorphisms with hypertension, endothelial damage, and inflammation in a Chilean pediatric population.
METHODS

Subjects
This study was designed as a cross-sectional study. Chilean children and adolescents of both sexes, ranging in age from 4 to 16 years, were invited to participate. We recruited 202 normotensive pediatric subjects with lower-middle, middle, and high socioeconomic status.
Trained nurses measured the blood pressure (BP) and heart rate in all subjects. Three measurements were obtained from the right arm at consecutive 5-minute intervals using an oscillometric method (Dinamap CARESCAPE V100; GE Healthcare, Medical Systems Information Technologies, Milwaukee, WI) with the subjects in a seated position. This measurement was performed with a cuff and bladder that were size-adjusted to the subject's upper-arm girth according to the published recommendations. 16, 17 Normotension in children was defined as an average systolic BP (SBP) and/or diastolic BP (DBP) <90th percentile for sex, age, and height. The BP index was determined using the observed BP/50th percentile BP level for sex, age, and stature using the normal values reported. 16 In adults, normotension was considered to be at least 2 different measurements of BP <140/90 mm Hg. Two subgroups of subjects were defined according to the BP of their parents: normotensive children with hypertensive parents (NH; n = 103) and normotensive children with normotensive parents (NN; n = 99). Clinical characteristics of subjects involved in the study are described in Table 1 .
Normotensive subjects in this study have an ethnic origin of Spanish/white-Amerindian. Briefly, the Chilean population originated through a biracial mixture of genes originating from the Spanish conquerors and a gene pool derived from the native Amerindians. 18, 19 The protocol followed in this study was written according to the guidelines of the Declaration of Helsinki and 
Biochemical and hormonal analysis
A total of 202 healthy, normotensive children were enrolled in the study. After an overnight fast, basal blood samples were obtained between 8:00 and 10:00 am. Serum aldosterone was assayed using a commercial radioimmunoassay kit (Coat-ACount Kit; Siemens, Los Angeles, CA). Based on our previous reports in normotensive children, plasma renin activity was measured by radioimmunoassay using a commercial kit (DiaSorin, Stillwater, MN). 20 The lower limit of the plasma renin activity assay was 0.1 ng/ml/hour. 21 Interleukin 6 (IL-6) was measured with an enzyme-linked immunosorbent assay (ELISA) using commercial reagents and standards according to the manufacturer's protocols (Bender Med Systems, Vienna, Austria). Interleukin 8 and tumor necrosis factor α (TNF-α) were measured with an ELISA using commercial kits (eBioscience, Vienna, Austria). Plasminogen activator inhibitor-1 (PAI-1) was measured with an ELISA (HYPHEN BioMed, Neuville sur Oise, France). Metalloproteinase-9 (MMP9) and metalloproteinase-2 (MMP2) activities were estimated by zymography, as described previously. 22 The results are expressed as arbitrary units of the number of changes with respect to the reference plasma used as an internal control. High-sensitivity C-reactive protein (hs-CRP) was measured with a nephelometric assay (BN ProSpec Systems; Siemens Healthcare Diagnostics Products, Marburg, Germany). The malondialdehyde (MDA) measurement quantifies the thiobarbituric acid-reactive compounds, as previously described. 23 At the same time, 12-hour nocturnal urine (between 7:00 pm and 7:00 am) samples were collected. Total 12-hour urine volumes were measured, and 50-ml aliquots were stored to measure creatinine and sodium. Urinary creatinine was measured by the Jaffe method with automated equipment (Modular Analytics, Roche, Germany). We also calculated the fractional sodium excretion. The serum, plasma, and urine samples were stored at −70°C until analysis.
Genetic analysis
Genomic DNA was isolated from peripheral leucocytes with the Lahiri method. 24 Real-time polymerase chain reaction (PCR) amplification of the intronic region (intron 1 and 3) of the RAC1 gene was performed using the RotorGene 6000 instrument (Corbett Research, Sydney, Australia). Hybridizing primers were designed to amplify both RAC1 gene polymorphisms: rs10951982, located in intron 1, and rs836478, located in intron 3. The primer sequences used were as follows: intron 1 (forward: 5'-CAGCAGGCAGAGGTTGTGGTA-3'; reverse: 5'-CATGAGTCGGCTGGAAGAAAGTTC-3´; size: 258bp) and exon-intron 3 boundary region (forward: 5´-CGGT GAATCTGGGCTTATG-3'; reverse: 5´-GCAAGTCCATAG GTAACATG-3´; size: 163bp). The reaction mixture contained 12.5 µl of sensimix High Resolution Melting (HRM) 2×, 1 µl of EvaGreen fluorescent dye (both reagents as part of the SensiMix HRM Kit; Bioline USA, Tauton, MA), 0.5 μM of both forward and reverse primers, 0.5 µl Gotaq (GoTaq Colorless Master Mix; Promega, Madison, WI), 2 μl of DNA (100 ng/ μl), and nuclease-free water up to 25 μl of the final volume. Three positive and negative controls were included (samples of DNA with each of the known genotypes) in each run. Thermal cycling consisted of an initial 8-minute hold at 95 °C, followed by a 15-second hold at 95 °C, a 15-second hold at 56 °C, and a 20-second hold at 72 °C for 40 cycles. Finally, the HRM step consisted of a ramp from 70 °C to 95 °C, rising 0.15 seconds at each step. Samples were analyzed with ClustalW software, and sequences were confirmed by Sanger sequencing at Macrogen (Seoul, Korea).
Data analysis
Differences in genotype frequencies in RAC1 polymorphisms were analyzed by χ 2 . A Hardy-Weinberg analysis was performed to identify the correspondence between the observed and calculated genotypes. The odds ratio (OR) identified the probability of the presence of the less prevalent allele, and a 95% confidence interval (CI) was used to estimate the precision of the OR. The results were expressed as median values (interquartile range (Q1-Q3)). The comparison between subject groups was performed using the KruskalWallis and Dunn's multiple comparisons tests with GraphPad Prism version 5.0 software (San Diego, CA). Differences were considered statistically significant at P < 0.05.
RESULTS
Identification and genotyping of RAC1 polymorphisms in pediatric subjects
We successfully identified both rs10951982 and rs836478 SNPs in the RAC1 gene in Chilean normotensive subjects using PCR-HRM technology. The PCR products, which were further analyzed by HRM, displayed 3 different melting curves that represented the 3 possible genotypes (homozygous, heterozygous, and alternative homozygous): GG, GA, and AA for the SNP rs10951982 and TT, TC, and CC for the SNP rs836478, respectively (Figure 1 ).
Frequency and genotype distribution
SNP rs10951982 in intron 1. The genotype distribution (GG, GA, AA) of the SNP rs10951982 (intron 1) was similar among subjects in the NH (68%, 30%, 2%, respectively) and NN groups (64%, 31%, 5%, respectively), and the allelic frequency distribution was also similar between both groups. We showed that the 2 groups of subjects were in Hardy-Weinberg equilibrium. The minor allele frequency, in this case that of adenine (A), was 0.17 and 0.20 for the NH and NN groups, respectively. These data were then analyzed by the OR method, which did not show any differences between the groups (Table 2) . SNP rs836478 in intron 3. The genotype distribution (TT, TC, CC) of the SNP rs836478 (intron 3) was different among subjects in the NH (25%, 45%, 29%, respectively) and NN groups (45%, 44%, 10%, respectively; P = 0.0005) ( Table 2 ). We showed that the 2 groups of subjects were in Hardy-Weinberg equilibrium. The minor allele frequency, in this case that of cytosine (C), was 0.52 in the NH group and 0.32 in the NN group (Table 2) . These data were also analyzed by the OR method, and the differences between groups were shown. The C allele occurred less frequently in the NN group than in the NH group (OR = 0.576; 95% CI = 0.36-0.92).
Associations of clinical and biochemical parameters
Biochemical parameters were analyzed in 202 normotensive children. We analyzed the association of polymorphisms with different clinical and biochemical parameters and also with oxidative stress, inflammation, endothelial dysfunction, and myocardial remodeling markers. The results are shown in Tables 3 and 4 . For the polymorphism rs10951982 (intron 1), we found that NN subjects with GA/ AA genotypes had a lower diastolic blood pressure index compared with NN subjects with the GG native genotype (median = 1.0, IQR = 0.95-1.10; vs. median = 1.075, IQR =1.01-1.16; P = 0.03) (Figure 2 ). However, we did not find any significant differences in parameters tested in the NH group (Table 3) .
For the polymorphism rs836478 (intron 3), we found that NN subjects with the alternative genotype (TT) had increased PAI-1 expression levels compared with NN subjects with the TC/CC genotype (median = 16.39, IQR =9.61-26.64; vs. median = 12.49, IQR = 7.96-18.88 ng/ml; P = 0.04) (Figure 2 ). In the NH group, subjects with the alternative genotype (TT) had decreased IL-6 expression levels compared with NH subjects with the TC/CC genotype (median = 8.8, IQR = 7.0-11.8; vs. median = 12.1, IQR = 8.3-14.6 pg/ml; P = 0.007) (Figure 2 ). MMP9 activity was increased in NH subjects with the TT genotype compared with NH subjects with the TC/CC genotype (median = 2.3, IQR = 1.6-3.2; vs. median = 1.6, IQR = 1.2-2.4 AU; P = 0.004) (Figure 2 ).
DISCUSSIOn
We studied and genotyped 2 polymorphisms in the RAC1 gene in a Chilean pediatric cohort. The SNP rs10951982 located in intron 1 had similar allelic and genotypic frequency between groups. However, we observed differences in the allelic frequency and genotypic distribution for the SNP rs836478, located in intron 3 of the RAC1 gene, between the NH and NN subjects. Additionally, both polymorphisms had a minor allele frequency similar to that which was published in the databases SNPs NCBI (www.ncbi.nlm.nih. gov/projects/SNP), HAPMAP (www.hapmap.ncbi.nlm.nih. gov/), and ENSEMBL (www.ensembl.org) for the Tuscan, European, and American populations.
We found an association between blood pressure and the RAC1 intron 1 polymorphism (rs10951982) in NN children. The DBP index was decreased in NN subjects with the GA/ AA genotype compared with subjects with the native GG genotype, suggesting the alternative A allele could be associated with normotension. One study supports this observation to date, demonstrating the SNP rs10951982 and its association with the expression of RAC1 decreases in the presence of the AA genotype. 15 In the pediatric cohort studied here, the presence of the polymorphism rs10951982 (G>A) lowered the DBP and might confer protection from hypertension in the vasculature of subjects with this polymorphism. Molecular explanations for this finding are speculative. The results from the bioinformatic assays show the SNP rs10951982 is located in a cis regulatory site in intron 1 of RAC1 gene and may also decrease the RAC1 gene expression in the presence of this polymorphism (data not shown). 15, 25 Although the polymorphism rs10951982 (GA/ AA) is associated with low BP in NN subjects, this SNP by itself cannot fully explain the association with BP and may require additional protector factors, which should be inherited from the subjects' normotensive parents.
The SNP rs836478 located in intron 3 was associated with some markers of inflammation and endothelial damage, which suggests the effects of Rac1 could be primarily at the vascular level. Indeed, some studies have shown that Rac1 has a pivotal role in the regulation of the gene expression involved in vascular cell function and inflammation, 26, 27 which would be associated with the hypertensive disease. 28 We found that NN subjects carrying the TT genotype have increased PAI-1 expression levels compared with NN subjects with the TC/CC genotype. Interestingly, previous studies have shown that Rac1-dependent reactive oxygen species formation promotes PAI-1 expression and increases its promoter activity in both endothelial and smooth muscle cells. [29] [30] [31] Thus, subjects carrying the TT genotype (SNP rs836478) would have increased PAI-1 expression levels, which is associated with a major risk for thrombosis and endothelial dysfunction.
We found that NH subjects carrying the rs836478 polymorphism (TT genotype) have decreased IL-6 levels compared with NH subjects with the TC/CC genotype, which may lead to increased inflammatory activity. IL-6 has significant anti-inflammatory effects, including the ability to induce synthesis of the interleukin 1 receptor antagonist to induce the release of soluble TNF receptors 32 and to inhibit TNF production of proinflammatory cytokines and MIP2. 33, 34 Therefore, decreasing IL-6 would compromise the development of hypertension because inflammatory mechanisms affect certain concentrations of cytokines that are crucial in the development and progression of organ damage in hypertensive patients. 35 This study also showed an elevation of MMP9 expression in NH subjects carrying a TT homozygous genotype compared with NH subjects with a TC/CC genotype, which could be an important risk factor in the development of hypertension because MMP9 is involved in extracellular matrix degradation, as well as in tissue remodeling, with both phenomena contributing to organ dysfunction (e.g., heart) and increasing the fibrosis. 36 These results are supported by previous studies showing that MMP9 levels are higher in hypertensive subjects than in normotensive control subjects. 37, 38 MMP9 is released from endothelial and smooth muscle cells after stimulation by hypertension-related mechanical stress on the vascular wall. In normotensives subjects, our data make it possible to suggest that the presence of the SNP rs836478 TT genotype could increase the expression of RAC1 and the production of reactive oxygen species through NADPH oxidase signaling and NFκB activation, which regulates MMP9 activity, providing a link between oxidative stress and 39 These results show that in the NH group there is an increased risk of biomarkers (IL-6 and MMP9) associated with the TT genotype of the SNP rs836478. However, there is a discrepancy because the risk genotype is more frequent in NN than NH. This discrepancy could be explained by the presence of other factors-inherited from the subjects' hypertensive parentsthat affect the biomarkers levels seen in this cohort.
In summary, we report the frequency and distribution of SNPs rs10951982 (intron 1, G/A) and rs836478 (intron 3, C/T) in the RAC1 gene in a Spanish-Amerindian pediatric cohort, showing a similar allelic frequency and genotypic distribution as described in the NCBI databases. These SNPs in the RAC1 gene are associated with some clinical (DBP) and biochemical (IL-6, MMP9, and PAI-1) parameters related to the development and progression of hypertension. However, we cannot rule out the possibility that additional factors, such as environmental or epigenetic factors, are contributing to the association of these polymorphisms with parameters of inflammation or the possibility that these additional factors are more significant. Thus, additional genetic and biochemical studies will be necessary to determine the risks in the phenotype of these subjects that these SNPs may have in later stages of life.
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